Complete Revascularization Via Inferior Part-sternotomy

Coronary Artery Bypass Grafting Clinical Trial

Official title:

Minimally Invasive Coronary Artery Bypass Grafting Achieving Complete Revascularization of Multivessel Coronary Artery Disease Via Inferior Part-Sternotomy (The ACRIS-MICABG Trial)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05835167
• Other study ID #: 2022-GSP-GG-23
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 5, 2023
• Est. completion date: May 4, 2035

Study information

• Verified date: April 2023
• Source: China National Center for Cardiovascular Diseases
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To verify the effectiveness and safety of minimally invasive coronary artery bypass grafting for complete revascularization of multivessel coronary artery disease via inferior part-sternotomy, We aim to randomize 260 patients undergoing isolated Coronary artery bypass grafting (CABG) to compare the ratios of complete revascularization between inferior part-sternotomy CABG and full median sternotomy CABG from 9 hospitals in China.

Description:

Coronary artery bypass grafting (CABG) has always been the gold standard for surgical treatment of coronary artery disease (CAD), especially for left main (LM) coronary disease, patients with high SYNTAX scores, and diabetes mellitus. By minimally invasive strategy, patients recover significantly faster in the early post-operative period. However, a prospective randomized controlled trials is needed to compare the ratios of complete revascularization between inferior part-sternotomy CABG and full median sternotomy CABG.

Objectives:

To verify the effectiveness and safety of minimally invasive coronary artery bypass grafting for complete revascularization of multivessel coronary artery disease via inferior part-sternotomy.

Study design:

This is a prospective, multicenter, open-label, randomized controlled trial. We aim to randomize 260 patients undergoing isolated CABG to compare the ratios of complete revascularization between inferior part-sternotomy CABG and full median sternotomy CABG from 9 hospitals in China. We consecutively screen patients during the study enrollment period and seek informed consent from all eligible patients. Patients who give informed consent are randomly assigned to undergo inferior part-sternotomy CABG or full median sternotomy CABG by a central randomization system. An expert group composed of three doctors with CABG qualifications will develop a plan achieving complete revascularization by coronary angiography images before the operation, including the number and location of proximal and distal anastomoses. The actual bypass procedure will be recorded and compared with the preoperative plan. We will follow-up participants until 10 years after the operation. To reduce the variation among surgeons, we require that all CABG are performed by qualified surgeons. The surgeons in this study needs to have experience in at least 100 cases of full median sternotomy CABG, and at least 5 cases of inferior part-sternotomy CABG.The ethics committees at all 9 participating hospitals approved this study.

Randomization A web-based central randomization system incorporated in the registration system is used for allocation (http://ccsr.cvs-china.com/). The randomization code with fixed block size is generated by SAS. Randomization is stratified by investigation center. When an eligible patient gives informed consent, the investigator logs in to the randomization webpage and obtain the random number along with treatment group (Inferior part-sternotomy or Full median sternotomy group) automatically distributed by the system after the basic patient information be confirmed. The statistician responsible for the randomization code and the staff who develops the Interactive Web-based Response (IWR) system are independent of each other.

Intervention Surgical procedure.The patient is placed in the supine position. Standard intubation and hemodynamic monitoring are used. Heparinization is standardized for on-pump CABG. The surgeon is given discretion to ensure that his choice in surgery would ensure the patient´s safety (including which graft to use or the choice of anatomic regions to revascularize). The surgeries are performed with the usual methods of cardiopulmonary bypass (CPB) with aortic cross-clamp technique. Myocardial protection strategies include blood cardioplegia and moderate hypothermia. For both types of surgeries, an excellent exposure is required.

Inferior part-sternotomy CABG.A sternal saw is used to split the sternum from the xiphoid process to the second intercostal space where the sternum is partially transected by turning the saw rightward. Remaining coronary bypassing techniques are same in both groups according to clinical practice and preference of the operator.

Full median sternotomy CABG. A midline skin incision is made over the sternum, starting from the sternal angle and extending slightly beyond the xiphoid process. The sternum is fully split by a sternal saw.

Medication. All participants are prescribed dual antiplatelet therapy with aspirin 100 mg plus clopidogrel 75 mg daily from the first day post-CABG until 3 months post-operation. Prescription of other concomitant medications such as β-blockers, statins, and antihypertensive agents is determined by local surgeons according to ACC/AHA guidelines.

The trial data will be analyzed on an intention-to-treat basis with patients included in the groups assigned at randomization, irrespective of future management and events.Demographic and clinical variables will be summarized as means (SDs) for continuous and counts (percentages) for categorical variables. Comparisons across the groups will be performed using a 2-tailed unpaired t test for continuous variables and the Pearson's χ2 test for categorical variables. A P value of less than 0.05 will be considered as statistically significant for all analyses.

Clinical events committee. All clinical events including myocardial infarction, stroke, target lesion revascularization, and death will undergo central adjudication by an independent clinical events committee (CEC).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 260
• Est. completion date: May 4, 2035
• Est. primary completion date: May 4, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

Patients who undergo primary isolated open-chest CABG with multi-vessel coronary disease(left main artery disease with right coronary artery disease,or three-vessel disease)

Exclusion Criteria:

1. Single vessel disease, double vessel disease, left main artery disease without right coronary artery disease.

2. Concomitant cardiac surgeries(i.e. valve repair or replacement, Maze surgery, left ventricular repair due to ventricular aneurysm).

3. Redo CABG.

4. Emergent CABG.

5. Left ventricular ejection fraction(EF=35%).

6. Severe atherosclerosis of the ascending aorta.

7. Subjects tend to choose surgical approach (via full median sternotomy/inferior part-sternotomy) .

8. Malignant tumor or other severe systemic diseases.

9. Severe renal insufficiency (i.e. creatinine >200 µmol/L).

10. Contraindications for dual antiplatelet therapy, such as active gastroduodenal ulcer.

11. Participant of other ongoing clinical trials.

Related Conditions & MeSH terms

• Coronary Artery Bypass Grafting
• Coronary Artery Disease
• Coronary Disease
• Multivessel Coronary Artery Disease
• Myocardial Ischemia

Intervention

Procedure:
• Inferior part-sternotomy
A midline skin incision of 8 to 10cm in length is made over the sternum, starting from 2-3cm below the sternal angle inferiorly and extending slightly beyond the xiphoid process. A sternal saw is used to split the sternum from the xiphoid process to the second intercostal space where the sternum is partially transected by turning the saw rightward.
• Full median sternotomy
A midline skin incision is made over the sternum, starting from the sternal angle and extending slightly beyond the xiphoid process. The sternum is fully split by a sternal saw.

Locations

Country	Name	City	State
n/a

Sponsors (9)

Lead Sponsor	Collaborator
China National Center for Cardiovascular Diseases	Baotou Central Hospital, Beijing Shijitan Hospital, Capital Medical University, Fuwai Yunnan Cardiovascular Hospital, Henan Provincial People's Hospital, Peking University International Hospital, Shenzhen Sun Yat-sen Cardiovascular Hospital, Tangshan Central Hospital, Xiamen Second Hospital

References & Publications (7)

Kleisli T, Cheng W, Jacobs MJ, Mirocha J, Derobertis MA, Kass RM, Blanche C, Fontana GP, Raissi SS, Magliato KE, Trento A. In the current era, complete revascularization improves survival after coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2005 Jun;129(6):1283-91. doi: 10.1016/j.jtcvs.2004.12.034. — View Citation

Lapierre H, Chan V, Sohmer B, Mesana TG, Ruel M. Minimally invasive coronary artery bypass grafting via a small thoracotomy versus off-pump: a case-matched study. Eur J Cardiothorac Surg. 2011 Oct;40(4):804-10. doi: 10.1016/j.ejcts.2011.01.066. Epub 2011 Mar 9. — View Citation

Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165. doi: 10.1093/eurheartj/ehy394. No abstract available. Erratum In: Eur Heart J. 2019 Oct 1;40(37):3096. — View Citation

Ong AT, Serruys PW. Complete revascularization: coronary artery bypass graft surgery versus percutaneous coronary intervention. Circulation. 2006 Jul 18;114(3):249-55. doi: 10.1161/CIRCULATIONAHA.106.614420. No abstract available. — View Citation

Sohn SH, Kang Y, Kim JS, Paeng JC, Hwang HY. Impact of Functional vs Anatomic Complete Revascularization in Coronary Artery Bypass Grafting. Ann Thorac Surg. 2023 Apr;115(4):905-912. doi: 10.1016/j.athoracsur.2022.10.029. Epub 2022 Nov 9. — View Citation

Sun HS, Ma WG, Xu JP, Sun LZ, Lu F, Zhu XD. Minimal access heart surgery via lower ministernotomy: experience in 460 cases. Asian Cardiovasc Thorac Ann. 2006 Apr;14(2):109-13. doi: 10.1177/021849230601400206. — View Citation

Veiga Oliveira P, Madeira M, Ranchordas S, Marques M, Almeida M, Sousa-Uva M, Abecasis M, Neves JP. Complete surgical revascularization: Different definitions, same impact? J Card Surg. 2021 Dec;36(12):4497-4502. doi: 10.1111/jocs.15986. Epub 2021 Sep 16. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete revascularization rate immediately after surgery	Most surgical groups have adopted the functional definition in their studies. We therefore elected to use a functional definition for complete revascularization in the present study. The coronary vascular tree was divided into 3 separate territories: the left anterior descending artery (LAD), the circumflex artery, and the right coronary artery (RCA).Functional completeness of revascularization is defined as all viable myocardial territories are reperfused, as at least one bypass graft for every diseased primary arterial territory	Immediately after surgery
Secondary	The harvest time of left Internal mammary artery (LIMA)	It is defined as the time from skin incision to clamping of the distal part of the LIMA.	During surgery
Secondary	Aortic cross-clamp time		During surgery
Secondary	Overall operation time	It is defined as the time from skin incision to skin sutured.	During surgery
Secondary	Intraoperative real-time blood flow at each anastomosis	It was evaluated intraoperatively using ultrasound flow measurements.	During surgery
Secondary	The total amount of postoperative chest tube drainage	This includes the amount of fluid of closed thoracic drainage or thoracentesis drainage due to pleural effusion during hospitalization.	Up to 4 weeks
Secondary	The graft patency rate by CTA at 5-7 days, 1 year, 3 years, 5 years, and 10 years after surgery	Graft occlusion is detected by computed tomography angiography (CTA). Grafts are graded into three levels: A (excellent), B (fair), or C (occluded). Contrast filling of the grafts, anastomoses, and coronary arteries beyond the graft are considered in each assessment. Grade A indicates that the graft is patent with =50% stenosis. Grade B indicates that graft stenosis is >50% but not occluded. When a graft does not fill with contrast at all, it is considered Grade C and included with string sign found in any segment (including proximal and distal anastomotic site, and main trunk). Both of these findings are considered together and referred to as occlusion in the analysis.The patency rate of grafts = number of grafts in grades A and B/total number of bypass grafts.	1week after the surgery;10 years after surgery
Secondary	The rate of major adverse cardiac or cerebrovascular events (MACCE) at 5-7 days, 1 year, 3 years, 5 years, and 10 years after surgery	MACCE: cardiac death, myocardial infarction, stroke, repeat revascularization and hospitalization for heart failure.; Myocardial infarction (troponin values >10 times the 99th percentile of upper reference limit in association with new Q waves).	1week after the surgery;10 years after surgery